ClinicalTrials.gg
RecruitingNCT06196567Updated Jul 18, 2024

Pulsed Electromagnetic Field Therapy on Muscle Strength and Function in Patients With End-stage of Knee Osteoarthritis

An interventional study of PEMF and exercise in Knee Osteoarthritis, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 50 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-07-18.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
50 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Osteoarthritis, Knee by Chinese University of Hong Kong — 9 open to participants now, 10 under way, none of them phase 3. Osteoarthritis, Knee · Chinese University of Hong Kong.

Planned enrollment
14th of 16
43 · median 64
Started
2024
with 3 others
No phase
15 of 20
8 open now
Registered
15th of 20
by date

Among the 20 studies in Osteoarthritis, Knee by Chinese University of Hong Kong, this one is the 14th largest by planned enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2024, is one of 15 with no phase, and was the 15th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

9 of the 20 studies in Osteoarthritis, Knee by Chinese University of Hong Kong are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 50 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Osteoarthritis, Knee by Chinese University of Hong Kong, or all of them as a file.
02

Study summary

End-stage OA knee is one of the most common musculoskeletal complaints, with over 34,000 patients waiting for joint replacement in Hong Kong and is expected to increase as the population continues to age constantly. The nominal waiting time for joint replacement in Hong Kong is long compared with many developed countries, averaging at 122 months, resulting in many elderly patients living with severe pain, limiting their daily activities. We are, therefore, in dire need to improve the well-being of this large and increasing group of patients as the capacity for operations remains limited.

It is important to maintain preoperative knee-extensor strength in the end-stage of knee OA awaiting TKR because the improvement of knee-extensor strength may postpone the need for surgery and increase the ability to perform functional activities after TKR at the same time.

PEMF exposure, on top of regular exercise training, may promote the secretion of myokine and in turn, promote muscle regeneration. These findings laid grounds for implementing PEMF treatment for end-stage knee OA patients to enhance muscle regeneration in periods with limited physical activity.

The novelty of this study is that this is the first RCT to examine if pulsed electromagnetic field therapy (PEMF), in addition to a standard rehabilitation, produces better muscle strength and functional performance before and after TKR in people with knee OA than either intervention alone. The impact of this study is particularly strong given end-stage patients waiting for knee replacement surgeries in Hong Kong.

Read the detailed description

Knee osteoarthritis (OA) is one of the most common chronic degenerative joint conditions affecting our ageing population. It is widely stated that OA is the leading cause of disability in elders due to discordant symptoms, such as pain and stiffness. Radiographic evidence of OA increased with age, from 8% in subjects younger than age 50, to over 60% in subjects aged 60 or above. Typically, conservative therapies that target symptoms are recommended as first- and second-line treatments for knee OA to reduce pain, stiffness, and activity limitations. However, when conservative therapies fail, they would then require total knee replacement (TKR). In 2022 to 2023, there were over 34,000 patients on the Hospital Authority (HA) waiting list for TKR. With only 3389 TKRs being performed, the nominal waiting time for TKR was outrageously long, 122 months in Hong Kong, as compared to an average of 9 months in Canada. Despite the efforts from the government to establish more joint replacement centres, the number of patients suffering from end-stage OA knees and requiring surgery will increase significantly as the population ages. Toward those requiring TKR, the excruciating pain would further cause significant functional impairment and lower health-related quality of life, which could eventually affect post-surgery outcomes. Although TKR appears to be an effective treatment in most people with end-stage Knee OA, 20%-40% of individuals remain dissatisfied. This is due to reduced leg strength occurring years after surgery, impaired functional capacity like poorer walking performance, greater deficits in physically demanding tasks such as stair climbing and poor performance of domestic duties .

The role of knee-extensor strength in the end-stage of Knee OA Knee-extensor muscle weakness has been regarded as a risk factor for knee OA. As shown, end-stage knee OA patients awaiting TKR had 35% reduced knee-extensor strength compared to healthy, age-matched individuals. In addition, pre-operative knee-extensor strength has also been found to be a predictor of postoperative functional ability up to a year following surgery. On average, patients would lose an additional 80% of their pre-operative knee-extensor strength shortly after TKA. Collectively, these data highlight the importance of maintaining preoperative knee-extensor strength in the end-stage of knee OA awaiting TKR and suggest that the improvement of knee-extensor strength may postpone the need for surgery and increase the ability to perform functional activities after TKR at the same time.

The role and limitation of prehabilitation before TKR The concept of preparing the body for a stressful event, such as surgery, has been named "prehabilitation". Prehabilitation was reported to positively affect knee OA symptoms and support patients' self-management of their knee OA condition, potentially postponing the need for surgery. As supported by the latest systematic review, it is important to focus on knee extensor muscle strength when evaluating the effects of prehabilitation before surgery in patients eligible for TKR. The review found that prehabilitation exercise could help to moderately increase knee extensor muscle strength and physical function and reduce pain. Moreover, a 30-40% increase in knee-extensor strength has been suggested to improve knee pain and disability. In conclusion, current prehabilitation has limited effects on improving sufficient knee extensor muscle strength.

Potential role of PEMF PEMF treatment utilizes a pulsed electromagnetic field to stimulate mitochondrial activity in skeletal muscle. Our group (Prof. Alfredo Franco-Obregon) showed that brief 10-minute exposure of 1 mT amplitude of PEMF (Quantum Tx) on myoblast in vitro could activate myogenesis. This can lead to a boost in repair and muscle regeneration via the release of myokines. Additionally, it plays an important role in regulating the production and secretion of myokine. Therefore, it is hypothesized that PEMF exposure, on top of regular exercise training, may promote the secretion of myokine and in turn promote muscle regeneration. These findings laid grounds to implement PEMF treatment for end-stage knee OA patients to enhance muscle regeneration in periods where limited physical activity is occurred. Also, this may help to set up a treatment regime for the PEMF device to impose myogenic effects, including exposure time per session, the number of treatment sessions and the duration of treatment.

Aims

The proposed project aims to set up a single-blinded randomized control trial to examine if pulsed electromagnetic field therapy (PEMF) in addition to a standard prehabilitation produces better muscle strength and functional performance before and after TKR in people with knee OA than either intervention alone.

To investigate the effect of PEMF in addition to a standard prehabilitation for muscle strength in end-stage OA knee patients.

To investigate the effect of PEMF in addition to a standard prehabilitation for knee symptoms and functional performance of OA knees in end-stage OA knee patients.

To investigate the effect of PEMF in addition to a standard prehabilitation for improving pain, function, and quality of life of OA knees in end-stage OA knee patients after surgery.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Knee Osteoarthritis
  • PEMF
  • Knee muscle strength
  • total knee replacement
  • knee pain and function
04

Who can participate

Ages eligible
50 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients end-stage knee OA over 50 waiting for TKR
  • Patient has been scheduled for TKR at Prince of Wales Hospital
  • Able to comply with the assessments and has given oral and written consent

Exclusion criteria

Exclusion Criteria:

  • Patients with connective tissue disorders or myositis condition
  • History of any Hip \& Knee joint replacement
  • Patients with acute immobility (i.e., post hip fracture or post-acute hospital admission)
  • Previous cases of any substances abuse
  • Patients already had TKR for one knee before
  • Patients are unable to transport themselves for intervention
  • Patients have any neuromuscular or neurodegenerative conditions
  • Patients have the history of inflammatory arthritis
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
43 participants (estimated)

Study arms

  • Active comparator
    active control group

    will receive the standard prehabilitation a physio-based exercise program designed to increase quadriceps muscle strength for 2 sessions per week for 8 weeks. Sessions will be performed at the same time (i.e., in the morning). The main programme comprised 5 sets of 10 repetitions for each exercise, with 60 rest between sets.

    Other: exercise

  • Experimental
    Pulsed Electromagnetic Field (PEMF)

    will receive the active PEMF treatment provided by a PEMF device (Quantum Tx, Singapore). Alternating leg will be exposed to PEMF for 10 minutes per session for 2 sessions per week for 8 weeks.

    Device: PEMF

  • Experimental
    standard prehabilitation plus PEMF intervention

    This group will have both the standard prehabilitation and PEMF intervention for 2 sessions a week for eight weeks.

    Device: PEMF · Other: exercise

Interventions

  • DevicePEMF

    Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions

  • Otherexercise

    do the exercise aimed at improving knee muscle strength,twice a week for 8 weeks before surgery

06

What researchers measure

Primary outcomes

  1. Changes of knee muscle strength

    The peak torque in kgf will be recorded with in 2 trials in the 5 seconds isometric muscle strength test.

    Time frame: Day 0, 4th week, 8th week after the commencement the intervention and 6th week, 3 months, and 12 months after the TKR surgery

Secondary outcomes

  1. Appendicular muscle mass

    The appendicular muscle mass will tested using dual x-ray absorptiometry (DXA)

    Time frame: Day 0, 4th week, 8th week after the commencement the intervention and 6th week, 3 months, and 12 months after the TKR surgery

  2. myokine evaluation-Brain-derived neurotrophic factor (BDNF)

    Quantitative analysis for BDNF and proteins related to muscle metabolism will be performed by Human Myokine Magnetic Bead Panel (Millipore) with Bioplex-200 bead-based suspension assay system (LKSIHS core facilities), or enzyme-linked immunosorbent assay (ELISA) and report with pg/ml.

    Time frame: Day 0, 8th week after the commencement the intervention and 6th week, 3 months, and 12th month after the TKR surgery

  3. myokine evaluation-Fibroblast growth factor-21 (FGF-21)

    Quantitative analysis for FGF-21 and proteins related to muscle metabolism will be performed by Human Myokine Magnetic Bead Panel (Millipore) with Bioplex-200 bead-based suspension assay system (LKSIHS core facilities), or enzyme-linked immunosorbent assay (ELISA) and report with pg/ml.

    Time frame: Day 0, 8th week after the commencement the intervention and 6th week, 3 months, and 12th month after the TKR surgery

  4. myokine evaluation-Interleukin-6 (IL-6)

    Quantitative analysis for IL-6 and proteins related to muscle metabolism will be performed by Human Myokine Magnetic Bead Panel (Millipore) with Bioplex-200 bead-based suspension assay system (LKSIHS core facilities), or enzyme-linked immunosorbent assay (ELISA) and report with pg/ml.

    Time frame: Day 0, 8th week after the commencement the intervention and 6th week, 3 months, and 12th month after the TKR surgery

  5. myokine evaluation-Interleukin-15 (IL-15)

    Quantitative analysis for IL-15 and proteins related to muscle metabolism will be performed by Human Myokine Magnetic Bead Panel (Millipore) with Bioplex-200 bead-based suspension assay system (LKSIHS core facilities), or enzyme-linked immunosorbent assay (ELISA) and report with pg/ml.

    Time frame: Day 0, 8th week after the commencement the intervention and 6th week, 3 months, and 12th month after the TKR surgery

  6. myokine evaluation-Irisin

    Quantitative analysis for Irisin and proteins related to muscle metabolism will be performed by Human Myokine Magnetic Bead Panel (Millipore) with Bioplex-200 bead-based suspension assay system (LKSIHS core facilities), or enzyme-linked immunosorbent assay (ELISA) and report with pg/ml.

    Time frame: Day 0, 8th week after the commencement the intervention and 6th week, 3 months, and 12th month after the TKR surgery

  7. myokine evaluation-Insulin-like growth factor 1 (IGF-1)

    Quantitative analysis for IGF-1 and proteins related to muscle metabolism will be performed by Human Myokine Magnetic Bead Panel (Millipore) with Bioplex-200 bead-based suspension assay system (LKSIHS core facilities), or enzyme-linked immunosorbent assay (ELISA) and report with pg/ml.

    Time frame: Day 0, 8th week after the commencement the intervention and 6th week, 3 months, and 12th month after the TKR surgery

  8. myokine evaluation-Insulin-Follistatin

    Quantitative analysis for Follistatin and proteins related to muscle metabolism will be performed by Human Myokine Magnetic Bead Panel (Millipore) with Bioplex-200 bead-based suspension assay system (LKSIHS core facilities), or enzyme-linked immunosorbent assay (ELISA) and report with pg/ml.

    Time frame: Day 0, 8th week after the commencement the intervention and 6th week, 3 months, and 12th month after the TKR surgery

  9. myokine evaluation-Insulin-C- terminal of troponin T1 (TNNT1)

    Quantitative analysis for TNNT1 and proteins related to muscle metabolism will be performed by Human Myokine Magnetic Bead Panel (Millipore) with Bioplex-200 bead-based suspension assay system (LKSIHS core facilities), or enzyme-linked immunosorbent assay (ELISA) and report with pg/ml.

    Time frame: Day 0, 8th week after the commencement the intervention and 6th week, 3 months, and 12th month after the TKR surgery

  10. Stair Ascent-Descent Assessment

    This test consisted of a stair climb, followed by a stair descent. The participants will begin from a standing start, and to be instructed to climb one flight (9 steps) of standard stairs by using the railing for balance if necessary. At the top of the stairs, they would immediately reverse in direction to descend from the same staircase. The time will be recorded. Less time means better function ability.

    Time frame: Day 0, 4th week, 8th week after the commencement the intervention and 6th week, 3 months, and 12 months after the TKR surgery

  11. Chair Stand Test

    The chair stand test is a reliable test for assessment for low limb strength in patients. Patients will be asked to sit on a solid chair with arms on shoulders and feet with shoulder width apart. Time of 5 repetition will recorded.Less time means better function ability.

    Time frame: Day 0, 4th week, 8th week after the commencement the intervention and 6th week, 3 months, and 12 months after the TKR surgery

  12. Postural Stability Assessment

    A force platform (Tekscan, U.S.) will be utilized to evaluate static postural control using the COP measures in static and dynamic postural control conditions. Sway path length of center of pressure (COP), velocity and ellipse area of COP will be recorded. These static postural conditions include stand on double leg with open and close eyes for 30s. The patients will perform two successful trials of each condition.

    Time frame: Day 0, 4th week, 8th week after the commencement the intervention and 6th week, 3 months, and 12 months after the TKR surgery

  13. Short-Form 36 (SF-36)

    The SF-36 health survey uses 36 questions to measure a patient's functional health and well-being from a patient's point of view. It is a reliable and validated measure that summarises the patients' physical and mental health.higher score indicate a better outcome in each subscape.

    Time frame: Day 0, 4th week, 8th week after the commencement the intervention and 6th week, 3 months, and 12 months after the TKR surgery

  14. Knee injury and Osteoarthritis Outcome Score

    Self-reported pain and physical function will be measured using the Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire. This 42-item questionnaire is divided into five subscales, which address pain, other disease symp¬toms, function in activities of daily living, function in sport and recreation, and quality of life. higher score indicate a better outcome in each subscape.

    Time frame: Day 0, 4th week, 8th week after the commencement the intervention and 6th week, 3 months, and 12 months after the TKR surgery

  15. International Physical Activity Questionnaire (IPAQ)

    The IPAQ is a questionnaire that assesses and monitors a patient's physical activity and inactivity level. This instrument sums up a patient's activity level per week.

    Time frame: Day 0, 4th week, 8th week after the commencement the intervention and 6th week, 3 months, and 12 months after the TKR surgery

  16. Visual Analogue Scale

    Severity of pain will be assessed using a visual analogue scale (VAS) which is a 10cm rating scale ranging from 'no pain at all' (score 0) to 'unbearable pain' (score 10). Patients will be instructed to mark a place on the horizontal line of the scale reflecting their knee pain severity.

    Time frame: Day 0, 4th week, 8th week after the commencement the intervention and 6th week, 3 months, and 12 months after the TKR surgery

07

Study locations

1 of 1 sites recruiting
  • Michael.Ong@Cuhk.Edu.Hk
    Hong Kong, NEW Territories, Hong Kong
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: starting 12 months after publication

Access criteria: Journal reviewers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jun 2026, 29 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 29 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2023
First posted
Jan 9, 2024
StartActual
Jan 1, 2024
Primary completionEst.
Jun 1, 2026
CompletionEst.
Dec 1, 2028
Last update
Jul 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06196567
Responsible party
Prof. Tim-Yun Michael ONG (Clinical Assistant Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Jan 9, 2024
Start date
Jan 1, 2024
Primary completion
Jun 1, 2026 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Jul 18, 2024

Study contacts

Michael Tim-Yun Ong
Contact
michael.ong@cuhk.edu.hk
26364171
Qianwen WANG
Contact
alicia157@link.cuhk.edu.hk
26364171
Michael Tim-Yun Ong
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion